Stem definition | Drug id | CAS RN |
---|---|---|
HIV protease inhibitors | 3609 | 174484-41-4 |
Dose | Unit | Route |
---|---|---|
1 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 23.70 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
June 22, 2005 | FDA | BOEHRINGER INGELHEIM |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hypomania | 232.60 | 161.02 | 45 | 982 | 4343 | 46680692 |
Jaundice cholestatic | 226.48 | 161.02 | 45 | 982 | 4984 | 46680051 |
Schizophrenia | 202.58 | 161.02 | 45 | 982 | 8523 | 46676512 |
Hepatotoxicity | 177.24 | 161.02 | 50 | 977 | 24959 | 46660076 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
HIV infection | 77.56 | 39.17 | 16 | 824 | 1652 | 29949986 |
Drug resistance | 70.69 | 39.17 | 25 | 815 | 20108 | 29931530 |
Viral load increased | 69.00 | 39.17 | 16 | 824 | 2838 | 29948800 |
Acquired immunodeficiency syndrome | 62.10 | 39.17 | 11 | 829 | 503 | 29951135 |
Mycobacterial infection | 54.33 | 39.17 | 12 | 828 | 1709 | 29949929 |
Opportunistic infection | 51.88 | 39.17 | 11 | 829 | 1293 | 29950345 |
Dyschromatopsia | 46.99 | 39.17 | 8 | 832 | 289 | 29951349 |
Viraemia | 41.54 | 39.17 | 9 | 831 | 1170 | 29950468 |
Source | Code | Description |
---|---|---|
ATC | J05AE09 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Protease inhibitors |
FDA MoA | N0000000246 | HIV Protease Inhibitors |
MeSH PA | D019380 | Anti-HIV Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D044966 | Anti-Retroviral Agents |
MeSH PA | D000998 | Antiviral Agents |
FDA EPC | N0000175889 | Protease Inhibitor |
CHEBI has role | CHEBI:35660 | hiv protease inhibitors |
CHEBI has role | CHEBI:36044 | anti-virus drug |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Human immunodeficiency virus infection | indication | 86406008 | DOID:526 |
Intracranial hemorrhage | contraindication | 1386000 | |
Hypercholesterolemia | contraindication | 13644009 | |
Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
Hereditary factor VIII deficiency disease | contraindication | 28293008 | DOID:12134 |
Hereditary factor IX deficiency disease | contraindication | 41788008 | DOID:12259 |
Hepatic failure | contraindication | 59927004 | |
Chronic type B viral hepatitis | contraindication | 61977001 | |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Procedure on central nervous system | contraindication | 118679007 | |
Neoplasm of brain | contraindication | 126952004 | DOID:1319 |
Inflammatory disease of liver | contraindication | 128241005 | |
Chronic hepatitis C | contraindication | 128302006 | |
Liver function tests abnormal | contraindication | 166603001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Lesion of brain | contraindication | 301766008 | |
Hypertriglyceridemia | contraindication | 302870006 | |
Surgical procedure | contraindication | 387713003 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Traumatic injury | contraindication | 417746004 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 5.13 | acidic |
pKa2 | 6.12 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Multidrug resistance protein 1 | Transporter | WOMBAT-PK | |||||||
Cathepsin D | Enzyme | Ki | 4.82 | CHEMBL | |||||
Pepsin A-5 | Enzyme | Ki | 5.70 | CHEMBL | |||||
Cathepsin E | Enzyme | Ki | 5.05 | CHEMBL | |||||
Pol polyprotein | Enzyme | INHIBITOR | IC50 | 7.52 | CHEMBL | CHEMBL | |||
CAAX prenyl protease 1 homolog | Enzyme | IC50 | 5.92 | CHEMBL |
ID | Source |
---|---|
4024917 | VUID |
N0000171602 | NUI |
D08605 | KEGG_DRUG |
4024917 | VANDF |
C1612190 | UMLSCUI |
CHEBI:63628 | CHEBI |
TPV | PDB_CHEM_ID |
CHEMBL222559 | ChEMBL_ID |
54682461 | PUBCHEM_CID |
C107201 | MESH_SUPPLEMENTAL_RECORD_UI |
7774 | INN_ID |
DB00932 | DRUGBANK_ID |
ZZT404XD09 | UNII |
190548 | RXNORM |
20182 | MMSL |
69882 | MMSL |
d05538 | MMSL |
010844 | NDDF |
418721002 | SNOMEDCT_US |
419409009 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Aptivus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0002 | SOLUTION | 100 mg | ORAL | NDA | 32 sections |
Aptivus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0003 | CAPSULE, LIQUID FILLED | 250 mg | ORAL | NDA | 32 sections |